Lung cancer in women

Lung Cancer: Targets and Therapy

Volumn 3, Issue , 2012, Pages 79-89

  Barrera Rodriguez, Raúl ^a   Morales Fuentes, Jorge ^a  

^a Institute of Respiratory Diseases   (Mexico)

Author keywords

Adenocarcinoma; Genetic differences; Genetic susceptibility; Lung cancer; Tobacco; Women

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; NICOTINE; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; DNA ADDUCT; DNA REPAIR; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; LIFESTYLE; LUNG CANCER; PAPILLOMAVIRUS INFECTION; REVIEW; SEX DIFFERENCE; SMOKING; SURVIVAL RATE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP A GENE; XERODERMA PIGMENTOSUM GROUP D GENE; XRCC1 GENE;

EID: 84878345350     PISSN: None     EISSN: 11792728     Source Type: Journal    
DOI: 10.2147/LCTT.S37319     Document Type: Review

References (126)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
3. American Society for Cancer. Cancer facts and figures for Hispanic/ Latinos 2009-2011. Available from: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFiguresforHispanicsLatinos/index. Accessed October 23, 2012.
4. Jemal A, Ward E, Thun MJ. Contemporary lung cancer trends among US women. Cancer Epidemiol Biomarkers Prev. 2005;14:582-585.
5. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe 2000-2004, and an overview of trends since 1975. Ann Oncol. 2010;21:1323-1360.
6. Cancer Incidence in Five Continents. Age-standardized incidence rates, four-digit rubrics, and age-standardized and cumulative incidence rates, three-digit rubrics. IARC Sci Publ. 1992;120:871-1011.
7. Vincent RG, Pickren JW, Lane WW, et al. The changing histopathology of lung cancer: a review of 1682 cases. Cancer. 1977;39:1647-1655.
8. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology. 2006;11:533-538.
9. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest. 2005;127:768-777.
10. Olak J, Colson Y. Gender differences in lung cancer: have we really come a long way, baby? J Thorac Cardiovasc Surg. 2004;128:346-351.
11. Medina FM, Barrera RR, Morales JF, Echegoyen RC, Chavarría JG, Rebora FT. Primary lung cancer in Mexico city: a report of 1019 cases. Lung Cancer. 1996;14:185-193.
12. Zatloukal P, Kubík A, Pauk N, Tomásek L, Petruzelka L. Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. Lung Cancer. 2003;41:283-293.
13. Albain KS, Unger J, Gotay CC; for the Southwest Oncology Group Lung Committee. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol. 2007;25 Suppl 18S:7549.
14. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
15. Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1:441-446.
16. Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol. 2010;21:2023-2028.
17. Surveillance Research Program, Cancer Statistics Branch. http://www.seer.cancer.gov/. Accessed Apr 2010.
18. Visbal AL, Williams BA, Nichols FC 3rd, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78:209-215.
19. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest. 2006;130:1796-1802.
20. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004; 45 Suppl 2:S3-S9.
21. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer. 2007;7:778-790.
22. Henschke CI, Yip R, Miettinen OS; International Early Lung Cancer Action Program Investigators. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006;296:180-184.
23. Gazdar AF, Thun MJ. Lung cancer, smoke exposure, and sex. J Clin Oncol. 2007;25:469-471.
24. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25:561-570.
25. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers - a review. Eur J Cancer. 2012;48:1299-1311.
26. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25:472-478.
27. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol. 1993;138: 281-293.
28. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996;88: 183-192.
29. Henschke CI, Yip R, Miettinen OS, et al. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006;296:180-184.
30. Thun MJ, Henley SJ, Calle EE. Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene. 2002;21:7307-7325.
31. Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst. 2004;96:826-834.
32. Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer. 1993;54:44-48.
33. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol. 2008;9:649-656.
34. Kuri-Morales PA, González-Roldán JF, Hoy MJ, Cortés-Ramírez M. Epidemiology of tobacco use in Mexico. Salud Publica Mex. 2006; 48 Suppl 1:S91-S98.Spanish.
35. Wardwell NR, Massion PP. Novel strategies for the early detection and prevention of lung cancer. Semin Oncol. 2005;32:259-268.
36. Alberg AJ, Ford JG, Samet JM, et al. Epidemiology of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines, 2nd ed. Chest. 2007;132 Suppl 3:S29-S55.
37. Kleinerman RA, Wang Z, Wang L, et al. Lung cancer and indoor exposure to coal and biomass in rural China. J Occup Environ Med. 2002;44:338-344.
38. Lissowska J, Bardin-Mikolajczak A, Fletcher T, et al. Lung cancer and indoor pollution from heating and cooking with solid fuels: the IARC international multicentre case-control study in Eastern/Central Europe and the United Kingdom. Am J Epidemiol. 2005;162: 326-333.
39. Gupta D, Boffetta P, Gaborieau V, Jindal SK. Risk factors of lung cancer in Chandigarh, India. Indian J Med Res. 2001;113:142-150.
40. Behera D, Balamugesh T. Indoor air pollution as a risk factor for lung cancer in women. J Assoc Physicians India. 2005;53:190-192.
41. Wu AH, Henderson BE, Pike MC, Yu MC. Smoking and other risk factors for lung cancer in women. J Natl Cancer Inst. 1985;74:747-751.
42. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79-115.
43. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. 2006;79:480-488.
44. Johnstone E, Benowitz N, Cargill A, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther. 2006;80:319-330.
45. Zeman MV, Hiraki L, Sellers EM. Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. J Womens Health Gend Based Med. 2002;11:147-153.
46. Melikian AA, Djordjevic MV, Hosey J, et al. Gender differences relative to smoking behavior and emissions of toxins from mainstream cigarette smoke. Nicotine Tob Res. 2007;9:377-387.
47. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227:115-124.
48. Higashi E, Fukami T, Itoh M, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos. 2007;35:1935-1941.
49. Hemminki K, Koskinen M, Rajaniemi H, Zhao C. DNA adducts, mutations, and cancer 2000. Regul Toxicol Pharmacol. 2000;32:264-275.
50. Rom WN, Tchou-Wong KM. Molecular and genetic aspects of lung cancer. Methods Mol Med. 2003;75:3-26.
51. Mollerup S, Berge G, Baera R, et al. Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer. 2006;119:741-744.
52. Lodovici M, Akpan V, Casalini C, Dolara P. Different susceptibility to polycyclic aromatic hydrocarbons (PAH)-induced DNA damage in lung tissue in male and female non-smokers. Biomarkers. 2000;5:447-451.
53. Yokota J, Shiraishi K, Kohno T. Genetic basis for susceptibility to lung cancer: Recent progress and future directions. Adv Cancer Res. 2010;109:51-72.
54. Cheng YW, Hsieh LL, Lin PP, et al. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen. 2001;37:304-310.
55. Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Differential expression of biomarkers in men and women. Semin Oncol. 2009;36: 553-565.
56. Larsen JE, Colosimo ML,Yang IA, Bowman R, Zimmerman PV, Fong KM. Risk of non-small cell lung cancer and the cytochrome P4501A1 Ile462Val polymorphism. Cancer Causes Control. 2005;16:579-585.
57. Uppstad H, Osnes GH, Cole KJ, Phillips DH, Haugen A, Mollerup S. Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. Lung Cancer. 2011;71:264-270.
58. Dally H, Edler L, Jäger B, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003;13:607-618.
59. Gresner P, Gromadzinska J, Wasowicz W. Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer. Lung Cancer. 2007;57:1-25.
60. Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML. Gender differences in genetic susceptibility for lung cancer. Lung Cancer. 2000;30:153-160.
61. Tang DL, Rundle A, Warburton D, et al. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis. 1998;19: 1949-1953.
62. Zhan P, Wang Q, Qian Q, Wei SZ, Yu LK. CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated metaanalysis and review. J Exp Clin Cancer Res. 2011;30:99.
63. Wang H, Jin G, Wang H, et al. Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. Cancer. 2009;115: 595-607.
64. Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer. 2011;73:138-146.
65. Vilmar A, Sørensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64:131-139.
66. Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol. 2011;28:1411-1417.
67. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair crosscomplementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy. Clin Cancer Res. 2004;10:4939-4943.
68. Holm B, Mellemgaard A, Skov T, Skov BG. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27:4254-4259.
69. Ren S, Zhou S, Wu F, et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer. 2012;75:102-109.
70. Yin Z, Zhou B, He Q, et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer. 15 2009;9:439.
71. Kiyohara C, Takayama K, Nakanishi Y. Lung cancer risk and genetic polymorphisms in DNA repair pathways: a meta-analysis. J Nucleic Acids. 2010;2010:701-760.
72. Zhan P, Wang Q, Wei SZ, et al. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies. J Thorac Oncol. 2010;5:1337-1345.
73. Yin Z, Ma R, Cui Z, Li M, He Q, Zhou B. Association of genetic polymorphism in the DNA repair gene XPD with risk of lung cancer in nonsmoking females. Zhongguo Fei Ai Za Zhi. 2006;9:492-496.Chinese.
74. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14:1797-1803.
75. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 2007;4:59-71.
76. Zhu ML, Wang M, Cao ZG, et al. Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis. PLoS One. 2012;7:e36293.
77. Dong S, Guo AL, Chen ZH, et al. RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol. 2010;3:10.
78. Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/ platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol. 2012;23:670-677.
79. Liu L, Yuan P, Wu C, et al. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2011;73:110-115.
80. Sreeja L, Syamala VS, Syamala V, et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol. 2008;134:645-652.
81. Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer. 2006;54:267-283.
82. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002;62:2141-2150.
83. Brinton LA, Gierach GL, Andaya A, et al. Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2011;20:900-911.
84. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2006;24:59-63.
85. Kabat GC, Miller AB, Rohan TE. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer. 2007;120:2214-2220.
86. Rodriguez C, Spencer Feigelson H, Deka A, et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev. 2008;17: 655-660.
87. Oh SW, Myung SK, Park JY, LymYL, Ju W. Hormone therapy and risk of lung cancer: a meta-analysis. J Womens Health (Larchmt). 2010;19: 279-288.
88. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis. Maturitas. 2010;65:198-204.
89. Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol. 2007;25:5785-5792.
90. Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res. 2005;11:5084-5089.
91. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res. 2005;11:7280-7287.
92. Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg. 2005;130:979-986.
93. Stabile LP, Dacic S, Land SR, et al. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 2011;17: 154-164.
94. Verma MK, Miki Y, Sasano H. Aromatase in human lung carcinoma. Steroids. 2011;76:759-764.
95. Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med. 2011;32:703-740.
96. Campling BG, el-Deiry WS. Clinical implications of p53 mutations in lung cancer. Methods Mol Med. 2003;75:53-77.
97. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat. 2003;21:229-239.
98. Anna L, Holmila R, Kovács K, et al. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary. Mutagenesis. 2009;24:475-480.
99. Ciardiello F, De Vita F, Orditura M, Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol. 2004;16: 130-135.
100. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367-1380.
101. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7: 169-181.
102. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118:257-262.
103. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006;24:1700-1704.
104. Riely GJ. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer. 2008;60 Suppl 2:S19-S22.
105. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
106. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-865.
107. Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer. 2008;60 Suppl 2: S23-S30.
108. Matsuo K, Ito H, Yatabe Y, et al. Risk factors differ for non-smallcell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci. 2007;98:96-101.
109. Li C, Sun Y, Fang R, et al. Lung adenocarcinomas with HER2- activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012;7:85-89.
110. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer. 2006;118: 1426-1429.
111. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6:201-205.
112. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010;29:49-60.
113. D'Arcangelo M, Cappuzzo F. K-Ras mutations in non-small-cell lung cancer: prognostic and predictive value. ISRN Molecular Biology. 2012:ID 837306, doi:10.5402/2012/837306.
114. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14:5731-5734.
115. Shriver SP, Bourdeau HA, Gubish CT, et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst. 2000;92:24-33.
116. Crystal AS, Shaw AT. New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol. 2011;9:207-214.
117. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046-2051.
118. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-3579.
119. Aguayo F, Castillo A, Koriyama C, et al. Human papillomavirus-16 is integrated in lung carcinomas: a study in Chile. Br J Cancer. 2007;97: 85-91.
120. Cheng YW, Wu MF, Wang J, et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res. 2007;67:10686-10693.
121. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer. 2004;101:1428-1436.
122. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 2001;61:2799-2803.
123. Yousem SA, Ohori NP, Sonmez-Alpan E. Occurrence of human papillomavirus DNA in primary lung neoplasms. Cancer. 1992;69: 693-697.
124. Kuang PP, Kong XJ. Lung cancer in Asian women. N A J Med Sci. 2009;2:69-73.
125. Nair HB, Luthra R, Kirma N, et al. Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation. Cancer Res. 2005;65:11164-11173.
126. Prabhu PR, Jayalekshmi D, Pillai MR. Lung cancer and human papilloma viruses (HPVs): examining the molecular evidence. J Oncol. 2012;2012:750270.